Specific Immunotherapy in Hymenoptera Venom Allergy and concomitant Malignancies. A retrospective follow-up focusing on efficacy and safety.

CONCLUSIONS: Efficacy and side effects of VIT in patients with Hymenoptera venom allergy and cancer are comparable to those without malignancy if cancer is in remission. This study shows that these patients are also eligible for VIT. PMID: 28675375 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28675375?dopt=Abstract

Source: Journal of Investigational Allergology and Clinical Immunology - July 4, 2017 Category: Allergy & Immunology Authors: Aeberhard J, Haeberli G, Müller UR, Helbling A Tags: J Investig Allergol Clin Immunol Source Type: research